Molecular Staging of Cancer

From the contents: The urokinase receptor (uPAR, CD87) as a target for tumor therapy Molecular regulation of urokinase receptor (u-PAR) gene expression as one potential concept for molecular staging and therapy Stromal cell involvement in cancer Inhibition of the tumor-associated urokinase-type plasminogen activation system: effects of high level synthesis of soluble urokinase receptor in ovarian and breast cancer cells in vitro and in vivo Molecular mechanisms of carcinogenesis in gastric cancer Clinical implications of molecular diagnosis in HNPCC Minimal residual disease in gastric cancer Minimal residual disease in breast cancer and gynecological malignancies Clinical implications of the EGF-receptor/ligand system for tumor progression and survival in gastrointestinal carcinomas: evidence for new therapeutic options Minimal residual disease in the bone marrow and peripheral blood of patients with metastatic breast cancer Estrogen receptor (ER) expression profile of disseminated epithelial tumor cells in the bone marrow of breast cancer patients Detection of circulating tumor cells in blood using an optimized density gradient centrifugation Antitumoral and antimetastatic effects of continuous particle mediated cytokine gene therapy Genetic subtyping of renal cell carcinoma by comparative genomic hybridization Telomere length and hTERT expression in patients with colorectal carcinoma Evaluation of the level of bFGF, VEGF, sICAM-1, sVCAM-1 in the serum of patients with thyroid cancer.

[1]  H. Allgayer,et al.  Targeted disruption of the K-Ras oncogene in an invasive colon cancer cell line down-regulates urokinase receptor expression and plasminogen-dependent proteolysis , 1999, British Journal of Cancer.

[2]  K. Becker,et al.  Prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in completely resected gastric cancer. , 1994, Cancer research.

[3]  Y. Kodera,et al.  Molecular diagnostic detection of free cancer cells in the peritoneal cavity of patients with gastrointestinal and gynecologic malignancies , 1999, Cancer Chemotherapy and Pharmacology.

[4]  F. Nagengast,et al.  The tumour spectrum in hereditary non‐polyposis colorectal cancer: A study of 24 kindreds in the netherlands , 1990, International journal of cancer.

[5]  H. Höfler,et al.  Urokinase (uPA) and its inhibitor PAI-1 are strong and independent prognostic factors in node-negative breast cancer , 2005, Breast Cancer Research and Treatment.

[6]  M. Osborne,et al.  Detection and management of bone marrow micrometastases in breast cancer. , 1994, Oncology.

[7]  K. Kinzler,et al.  Mutations of GTBP in genetically unstable cells. , 1995, Science.

[8]  S. Shetty,et al.  Posttranscriptional regulation of urokinase receptor mRNA: identification of a novel urokinase receptor mRNA binding protein in human mesothelioma cells , 1997, Molecular and cellular biology.

[9]  H. Allgayer,et al.  Individual development and uPA–receptor expression of disseminated tumour cells in bone marrow: A reference to early systemic disease in solid cancer , 1995, Nature Medicine.

[10]  U. Weidle,et al.  Recombinant soluble urokinase receptor as a scavenger for urokinase‐type plasminogen activator (uPA) , 1994, FEBS letters.

[11]  D. Cines,et al.  Overexpression of urokinase receptor increases matrix invasion without altering cell migration in a human osteosarcoma cell line. , 1993, Cancer research.

[12]  Hua Tang,et al.  The Urokinase-type Plasminogen Activator Receptor Mediates Tyrosine Phosphorylation of Focal Adhesion Proteins and Activation of Mitogen-activated Protein Kinase in Cultured Endothelial Cells* , 1998, The Journal of Biological Chemistry.

[13]  P. Sistonen,et al.  Screening reduces colorectal cancer rate in families with hereditary nonpolyposis colorectal cancer. , 1995, Gastroenterology.

[14]  L. Ossowski,et al.  Antibodies to plasminogen activator inhibit human tumor metastasis , 1983, Cell.

[15]  U. Cavallaro,et al.  A conjugate between human urokinase and saporin, a type-1 ribosome-inactivating protein, is selectively cytotoxic to urokinase receptor-expressing cells. , 1993, The Journal of biological chemistry.

[16]  P. Jensen,et al.  Protein kinase C mediates up‐regulation of urokinase and its receptor in the migrating keratinocytes of wounded cultures, but urokinase is not required for movement across a substratum in vitro , 1996, Journal of cellular physiology.

[17]  F. Blasi,et al.  Proteolytic cleavage of the urokinase receptor substitutes for the agonist‐induced chemotactic effect. , 1996, The EMBO journal.

[18]  G. Riethmüller,et al.  Monoclonal antibodies in the detection and therapy of micrometastatic epithelial cancers , 1992, Current Biology.

[19]  F. Blasi,et al.  Urokinase-type plasminogen activator is expressed in stromal cells and its receptor in cancer cells at invasive foci in human colon adenocarcinomas. , 1991, The American journal of pathology.

[20]  H. Allgayer,et al.  Tumor-associated proteolysis and prognosis: new functional risk factors in gastric cancer defined by the urokinase-type plasminogen activator system. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  D. Boyd,et al.  Requirement of an Upstream AP-1 Motif for the Constitutive and Phorbol Ester-inducible Expression of the Urokinase-type Plasminogen Activator Receptor Gene* , 1996, The Journal of Biological Chemistry.

[22]  D. Ward,et al.  Mutation in the DNA mismatch repair gene homologue hMLH 1 is associated with hereditary non-polyposis colon cancer , 1994, Nature.

[23]  L. Ossowski,et al.  In vivo invasion of modified chorioallantoic membrane by tumor cells: the role of cell surface-bound urokinase , 1988, The Journal of cell biology.

[24]  A. Vaheri,et al.  Ultrastructural localization of plasma membrane-associated urokinase- type plasminogen activator at focal contacts , 1988, The Journal of cell biology.

[25]  R. Zeillinger,et al.  Quantification of uPA receptor expression in human breast cancer cell lines by cRT-PCR , 2005, Breast Cancer Research and Treatment.

[26]  L. Ossowski,et al.  Tumor Dormancy Induced by Downregulation of Urokinase Receptor in Human Carcinoma Involves Integrin and MAPK Signaling , 1999, The Journal of cell biology.

[27]  H. Allgayer,et al.  Tumor-associated proteases and inhibitors in gastric cancer: analysis of prognostic impact and individual risk protease patterns , 2004, Clinical & Experimental Metastasis.

[28]  K. Kinoshita,et al.  Prediction of peritoneal micrometastasis by peritoneal lavaged cytology and reverse transcriptase-polymerase chain reaction for matrix metalloproteinase-7 mRNA. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[29]  H. Petty,et al.  Urokinase-Type Plasminogen Activator Receptors Associate with β1 and β3 Integrins of Fibrosarcoma Cells: Dependence on Extracellular Matrix Components , 1997 .

[30]  M. Duffy,et al.  Urokinase-plasminogen activator, a new and independent prognostic marker in breast cancer. , 1990, Cancer research.

[31]  Y. Kook,et al.  The effect of antisense inhibition of urokinase receptor in human squamous cell carcinoma on malignancy. , 1994, The EMBO journal.

[32]  N. Brünner,et al.  Urokinase and plasminogen activator inhibitor type 1 in pulmonary adenocarcinoma. , 1994, Cancer research.

[33]  F. Hucho,et al.  Downstream targets of urokinase-type plasminogen-activator-mediated signal transduction. , 1998, European journal of biochemistry.

[34]  S. Rosenberg,et al.  Identification of the urokinase receptor as an adhesion receptor for vitronectin. , 1994, The Journal of biological chemistry.

[35]  K. Danø,et al.  The murine urokinase-type plasminogen activator receptor gene. , 1994, The Journal of biological chemistry.

[36]  B. Cesana,et al.  Bone marrow-disseminated tumor cells in patients with carcinoma of the esophagus or cardia. , 2001, Surgery.

[37]  E. Lengyel,et al.  Elevated urokinase-type plasminogen activator receptor expression in a colon cancer cell line is due to a constitutively activated extracellular signal-regulated kinase-1-dependent signaling cascade , 1997, Oncogene.

[38]  D. Rifkin,et al.  Expression of the urokinase receptor in vascular endothelial cells is stimulated by basic fibroblast growth factor , 1991, The Journal of cell biology.

[39]  H. Friess,et al.  Enhanced expression of urokinase plasminogen activator and its receptor in pancreatic carcinoma. , 1997, British Journal of Cancer.

[40]  L. Bolund,et al.  Assignment of the urokinase-type plasminogen activator receptor gene (PLAUR) to chromosome 19q13.1-q13.2. , 1992, American journal of human genetics.

[41]  Jian-ning Liu,et al.  Urokinase-type Plasminogen Activator-induced Monocyte Adhesion Requires a Carboxyl-terminal Lysine and cAMP-dependent Signal Transduction (*) , 1995, The Journal of Biological Chemistry.

[42]  J. Mecklin,et al.  The International Collaborative Group on Hereditary Non-Polyposis Colorectal Cancer (ICG-HNPCC) , 1991, Diseases of the colon and rectum.

[43]  S. Capaccioli,et al.  Reversion of the invasive phenotype of transformed human fibroblasts by anti-messenger oligonucleotide inhibition of urokinase receptor gene expression. , 1995, Cancer research.

[44]  W. Yu,et al.  Requirement for Specific Proteases in Cancer Cell Intravasation as Revealed by a Novel Semiquantitative PCR-Based Assay , 1998, Cell.

[45]  H. Allgayer,et al.  Clinical value of extended biologic staging by bone marrow micrometastases and tumor-associated proteases in gastric cancer. , 1997, Annals of surgery.

[46]  D. Boyd.  Examination of the effects of epidermal growth factor on the production of urokinase and the expression of the plasminogen activator receptor in a human colon cancer cell line. , 1989, Cancer research.

[47]  H. Allgayer,et al.  Transactivation of the Urokinase-type Plasminogen Activator Receptor Gene through a Novel Promoter Motif Bound with an Activator Protein-2α-related Factor* , 1999, The Journal of Biological Chemistry.

[48]  J. Cajot,et al.  The role of the urokinase receptor in extracellular matrix degradation by ht29 human colon carcinoma cells , 1993, International journal of cancer.

[49]  N. Brünner,et al.  Expression of uPA and its receptor by both neoplastic and stromal cells during xenograft invasion , 1994, International journal of cancer.

[50]  H. Höfler,et al.  Modulation of urokinase and urokinase receptor gene expression in human renal cell carcinoma. , 1995, The American journal of pathology.

[51]  G. Liu,et al.  Co‐expression of urokinase, urokinase receptor and PAI‐1 is necessary for optimum invasiveness of cultured lung cancer cells , 1995, International journal of cancer.

[52]  J. Witte,et al.  Epithelial tumor cells in bone marrow of patients with colorectal cancer: immunocytochemical detection, phenotypic characterization, and prognostic significance. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[53]  H. Allgayer,et al.  Prognostic factors in gastric cancer , 1997, The British journal of surgery.

[54]  C. Zandonella,et al.  Urokinase receptor antagonists inhibit angiogenesis and primary tumor growth in syngeneic mice. , 1996, Cancer research.

[55]  T. Urano,et al.  Cancer cells overexpress mRNA of urokinase‐type plasminogen activator, its receptor and inhibitors in human non‐small‐cell lung cancer tissue: Analysis by Northern blotting and in situ hybridization , 1998, International journal of cancer.

[56]  P. Cohen,et al.  Analysis of pp60c-src protein kinase activity in human tumor cell lines and tissues. , 1986, The Journal of biological chemistry.

[57]  N. Copeland,et al.  The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer. , 1993, Cell.

[58]  F. Schildberg,et al.  Comparative analyses of bone marrow micrometastases in breast and gastric cancer , 1996, International journal of cancer.

[59]  K. Crabtree.  Genetics, Natural History, Tumor Spectrum, and Pathology of Hereditary Nonpolyposis Colorectal Cancer: An Updated Review , 1994 .

[60]  D. Boyd,et al.  Examination of the role of the urokinase receptor in human colon cancer mediated laminin degradation. , 1989, Cancer research.

[61]  H. Allgayer,et al.  Urokinase plasminogen activator receptor (uPA-R): one potential characteristic of metastatic phenotypes in minimal residual tumor disease. , 1997, Cancer research.

[62]  H. Nekarda,et al.  Strong prognostic impact of tumor-associated urokinase-type plasminogen activator in completely resected adenocarcinoma of the esophagus. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[63]  M. Duffy,et al.  Urokinase-type plasminogen activator and outcome in Dukes' B colorectal cancer , 1994, The Lancet.

[64]  H. Allgayer,et al.  Stimulation of urokinase-type plasminogen activator receptor expression by PMA requires JNK1-dependent and -independent signaling modules , 1998, Oncogene.

[65]  H. Verspaget,et al.  Plasminogen activators in normal tissue and carcinomas of the human oesophagus and stomach. , 1993, Gut.

[66]  B. M. Mueller,et al.  The urokinase-type plasminogen activator receptor, a GPI-linked protein, is localized in caveolae , 1995, The Journal of cell biology.

[67]  J. Jankun,et al.  Expression and localization of elements of the plasminogen activation system in benign breast disease and breast cancers , 1993, Journal of cellular biochemistry.

[68]  W. Hohenberger,et al.  Immunocytology improves prognostic impact of peritoneal tumour cell detection compared to conventional cytology in gastric cancer. , 1999, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[69]  H. Juhl,et al.  Isolated tumor cells are frequently detectable in the peritoneal cavity of gastric and colorectal cancer patients and serve as a new prognostic marker. , 1998, Annals of surgery.

[70]  S. Waxman,et al.  Induction of cell migration by pro-urokinase binding to its receptor: possible mechanism for signal transduction in human epithelial cells , 1994, The Journal of cell biology.

[71]  W. Hohenberger,et al.  Prognostic value of microscopic peritoneal dissemination , 2000, Diseases of the colon and rectum.

[72]  W. Knapp,et al.  Urokinase Plasminogen Activator Receptor, ~2-Integrins, and Src-kinases within a Single Receptor Complex of Human Monocytes By Jan Bohuslav, .1 V~clav Ho~ej~f,~ t Cornelia Hansmann,* , 1995 .

[73]  S. Mandriota,et al.  Vascular Endothelial Growth Factor Increases Urokinase Receptor Expression in Vascular Endothelial Cells (*) , 1995, The Journal of Biological Chemistry.

[74]  D. Boyd,et al.  Role of the urokinase receptor in facilitating extracellular matrix invasion by cultured colon cancer. , 1991, Cancer research.

[75]  P J Farnham,et al.  Transcription initiation from the dihydrofolate reductase promoter is positioned by HIP1 binding at the initiation site. , 1990, Molecular and cellular biology.

[76]  C. Cartwright,et al.  Activation of the pp60c-src protein kinase is an early event in colonic carcinogenesis. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[77]  K. Pantel,et al.  Prognostic significance of bone marrow micrometastases in patients with gastric cancer. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[78]  H. Verspaget,et al.  Urokinase receptor and colorectal cancer survival , 1994, The Lancet.

[79]  R. Huber,et al.  Structural and functional analyses of benzamidine-based inhibitors in complex with trypsin: implications for the inhibition of factor Xa, tPA, and urokinase. , 1998, Journal of medicinal chemistry.

[80]  K. Jauch,et al.  Nachweis und Bedeutung der Tumorzelldissemination beim Magenkarzinom , 1998, Der Onkologe.

[81]  A. Grothey,et al.  Serum levels of soluble intercellular adhesion molecule-1 (ICAM-1, CD54) in patients with non-small-cell lung cancer: correlation with histological expression of ICAM-1 and tumour stage. , 1998, British Journal of Cancer.

[82]  Robin J. Leach,et al.  Mutations of a mutS homolog in hereditary nonpolyposis colorectal cancer , 1993, Cell.

[83]  K. Danø,et al.  The Plasminogen Activation System in Human Colon Cancer : Messenger RNA for the Inhibitor PAI-1 Is Located in Endothelial Cells in the Tumor , 2006 .

[84]  E. Appella,et al.  Cloning and expression of the receptor for human urokinase plasminogen activator, a central molecule in cell surface, plasmin dependent proteolysis. , 1990, The EMBO journal.

[85]  B. Ljung,et al.  The urokinase receptor is expressed in invasive breast cancer but not in normal breast tissue. , 1994, Cancer research.

[86]  J. Skibber,et al.  Transcriptional activation of the urokinase receptor gene in invasive colon cancer , 1994, International journal of cancer.

[87]  Michael V. Doyle,et al.  Regulation of Integrin Function by the Urokinase Receptor , 1996, Science.

[88]  F. Blasi,et al.  Recycling of the urokinase receptor upon internalization of the uPA:serpin complexes , 1997, The EMBO journal.

[89]  H. Allgayer,et al.  The prognostic impact of the urokinase-type plasminogen activator system is associated with tumour differentiation in gastric cancer. , 1996, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[90]  H. Allgayer,et al.  Transcriptional Induction of the Urokinase Receptor Gene by a Constitutively Active Src , 1999, The Journal of Biological Chemistry.

[91]  J. Kleibeuker,et al.  Hereditary nonpolyposis colorectal cancer: results of long-term surveillance in 50 families. , 1995, European journal of cancer.

[92]  S. Curley,et al.  Increase in activity and level of pp60c-src in progressive stages of human colorectal cancer. , 1993, The Journal of clinical investigation.

[93]  B. Nielsen,et al.  An alternatively spliced variant of mRNA for the human receptor for urokinase plasminogen activator , 1993, FEBS letters.

[94]  K. Helin,et al.  A conserved TATA-less proximal promoter drives basal transcription from the urokinase-type plasminogen activator receptor gene. , 1995, Blood.

[95]  N. Tanaka,et al.  Soluble intercellular adhesion molecule-1 and natural killer cell activity in gastric cancer patients. , 1998, Research communications in molecular pathology and pharmacology.